Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies that target harmful bacteria linked to chronic diseases like cystic fibrosis and diabetic foot osteomyelitis. Utilizing proprietary platforms—BOLT for engineered phage cocktails and PST for personalized phage matching—BiomX designs natural and synthetic bacteriophage treatments. Its business model focuses on precise bacterial targeting to address antibiotic resistance, serving patients through clinical development and potential future commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.